Press releases

Positive results from first Phase I/II clinical study of VAL-070 in hypercholesterolemia

July 10th 2018

VALBIOTIS announced Phase I/II positive results on VAL-070 in hypercholesterolemia, which validate safety, tolerance and blood LDL-cholesterol as the primary endpoint of the Phase II clinical studies.

Read more

Cécile Merle appointed to the position of Quality Assurance Director

June 19th 2018

VALBIOTIS announces the appointment of Cécile Merle to the position of Quality Assurance Director

Read more

VALBIOTIS confirms its deployment in the United-States, to prepare the future commercialization of VALEDIA

June 7th 2018

VALBIOTIS announces its integration into the French Tech in Boston, Massachusetts, and the development of investors relations in the USA.

Read more

The clinical development of VALEDIA® initiated in the USA

May 15th 2018

VALBIOTIS announces the authorization received to launch the international REVERSE-IT study in the United States as well as first discussions with the FDA.

Read more